Chemeca Drugs is an API manufacturer based in India. It holds 12 active US drug master files across a filed portfolio of 13 molecules. Its most recent recorded inspection, by US FDA, closed on 3 March 2023 as NAI. Customs aggregates show $11.8M of exports covering 98 molecules to 8 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapalli District, India | 3010630993 |
| Molecule | Regulators | Docs |
|---|---|---|
| Bupropion | US FDA | 1 |
| Carisoprodol | US FDA | 1 |
| Celecoxib | US FDA | 1 |
| Clopidogrel | US FDA | 1 |
| Clopidogrel Bisulfate | SFDA (Saudi Arabia) | 1 |
| Diltiazem | US FDA | 1 |
| Fexofenadine | US FDA | 1 |
| Fluoxetine | US FDA | 1 |
| Hydralazine | US FDA | 1 |
| Pirfenidone | US FDA | 1 |
| Quetiapine | US FDA | 1 |
| Rifaximin | US FDA | 1 |
| Sertraline | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3.1M | 2 |
| 2025 | Not reported | $11.8M | 8 |
| 2024 | Not reported | $13.0M | 8 |
| 2023 | Not reported | $6.1M | 8 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Chemeca Drugs comes back tiered against every other supplier able to file there.
Start for free